Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA; Department of Urology, Sorbonne University, GRC n°5, Predictive Onco-Urology, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.
Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
Eur Urol Focus. 2021 Sep;7(5):964-972. doi: 10.1016/j.euf.2020.10.006. Epub 2020 Nov 5.
Pure single-site robot-assisted extraperitoneal prostatectomy (EPP) using a single-port (SP) robotic platform has been shown to be feasible and safe in previous descriptive studies.
To compare the perioperative outcomes of patients undergoing SP-EPP versus conventional multiport (MP) transperitoneal robot-assisted radical prostatectomy (RARP).
DESIGN, SETTING, AND PARTICIPANTS: From January 2019 to January 2020, data of 100 consecutive patients who underwent SP-EPP performed by the same surgeon and 110 consecutive patients who underwent MP-RARP by three surgeons from the same institution were prospectively collected.
All SP-EPPs were performed in a pure single-site fashion without Trendelenburg.
Demographic characteristics as well as intra- and postoperative data of patients in both groups were analyzed. Quantitative data were described in terms of median and quartiles.
After SP-EPP, the rate of patients discharged the same day was nine times higher than that after MP-RARP (p < 0.001), and the median length of postoperative hospital stay was significantly shorter: 4.3 h (interquartile range [IQR] 3.3-17.4) versus 26.1 h (IQR 21.5-44.8). The rate of opioid use in the hospital and after discharge in the SP group was at least half that in the MP group (respectively, 32% vs 64%, p < 0.001, and 35% vs 87%, p < 0.001). The overall positive surgical margin rate as well as continence rate at 12 mo (85% vs 88%, p = 0.97) and the prostate-specific antigen relapse-free survival (p = 0.09) were statistically comparable between the SP and MP groups.
Pure single-site SP-EPP was associated with a shorter length of stay as well as a decreased need for postoperative pain medication and narcotic administration in comparison with conventional transperitoneal multiport prostatectomy, with comparable postoperative complications and readmission rate.
Surgical treatment of localized prostate cancer using a single-port robotic platform allows for a shorter hospital stay, less pain, and less opioid use than conventional robotic surgery without more morbidity. TAKE HOME MESSAGE: Pure single-site single-port extraperitoneal prostatectomy was associated with a shorter length of stay as well as a decreased need for postoperative pain medication and narcotic administration in comparison with conventional transperitoneal multiport prostatectomy, with comparable postoperative complication and readmission rate.
在先前的描述性研究中,已经证明了使用单端口(SP)机器人平台的纯单部位机器人辅助腹膜外前列腺切除术(EPP)是可行且安全的。
比较接受 SP-EPP 与传统多端口(MP)经腹机器人辅助根治性前列腺切除术(RARP)的患者的围手术期结局。
设计、设置和参与者:从 2019 年 1 月至 2020 年 1 月,前瞻性收集了 100 例连续接受同一位外科医生施行的 SP-EPP 的患者和 110 例连续接受来自同一机构的三位外科医生施行的 MP-RARP 的患者的数据。
所有 SP-EPP 均以纯单部位方式进行,不使用特伦德伦堡体位。
分析两组患者的人口统计学特征以及围手术期数据。定量数据以中位数和四分位数表示。
在 SP-EPP 后,当天出院的患者比例是 MP-RARP 的九倍(p<0.001),术后住院时间中位数明显缩短:4.3 小时(四分位距 [IQR] 3.3-17.4)与 26.1 小时(IQR 21.5-44.8)。SP 组在医院和出院后使用阿片类药物的比例至少是 MP 组的一半(分别为 32%比 64%,p<0.001,和 35%比 87%,p<0.001)。SP 和 MP 组的总阳性切缘率以及 12 个月时的控尿率(85%比 88%,p=0.97)和前列腺特异性抗原无复发生存率(p=0.09)在统计学上无差异。
与传统经腹多端口前列腺切除术相比,纯单部位 SP-EPP 与较短的住院时间以及减少术后疼痛药物和阿片类药物的需求相关,且术后并发症和再入院率相当。
使用单端口机器人平台对局限性前列腺癌进行手术治疗,与传统机器人手术相比,可缩短住院时间、减轻疼痛并减少阿片类药物的使用,且不会增加发病率。
与传统的经腹多端口前列腺切除术相比,纯单部位单端口腹膜外前列腺切除术可缩短住院时间,减少术后疼痛药物和阿片类药物的使用,且术后并发症和再入院率相当。